免疫导向化疗对阻抑肺癌术后复发的临床观察

Clinical observation of immunological import chemotherapy preventing recurrence of postoperative lung cancer

目的 观察免疫导向化疗治疗术后肺癌以阻抑肺癌复发的临床疗效。方法 采用转铁蛋白受体单抗(TFR-M)与表阿霉素(EADM)、顺铂(DDP)的偶联物对19例术后肺癌进行免疫导向化疗(导向组),并以12例术后肺癌以EADM、DDP的全身化疗(全身组)作对照观察。结果 导向组2年的年控制率(89.5％、73.7％)均高于全身组(33.3％、8.3％);其年复发率(10.5％、26.3％)均明显低于全身组(66.7％、91.7％)。导向组的中位生存期(24.6个月)是全身月(12.2个月)2倍多。结论 应用TFR-M为“载体”的免疫导向化疗能把化学抗癌药物专一地导入肺内残留的肺癌细胞处,提高了肺内癌灶局部的化疗药物浓度,是一种疗效好、毒性低的抗癌疗法。

Objective To observe the clinical effect of inhibiting of lung cancer recurrence after immunologi-cal import chemotherapy. Methods 19 cases of postoperative lung cancer were treated by immunological import chemotherapy(IIC) with coupling drugs of transferin receptor-monoclonal (TFR-M) antibody, EADM and DDP, while it was compared with 12 cases using general chemotherapy (GC) with EADM and DDP. Results The annual control rate of lung cancer of IIC group(89.9% ) was higher than that of GC group(33.3% ) ;two years control rate of IIC group(73.7% ) was much higher than GC group(8.3% ). The annual recurrent rate of IIC group(10. 5%) and two years recurent rate( 26.3 % ) of which were obviously lower than that of GC group (66.7 % and 91.7%). The mean survival period of IIC group was 24.6 months,more than twice of that of GC group(l2.2 months).Conclusion TFR-M antibody being the carrier of immunological import chemotherapy can be concentrated to lead the chemical anti-cancer drugs to cancer' s cells of surviving lung tissue increase local concentration of chemotherapeutic drugs in lung cancer focus. It is suggested that immunological import chemotherapy is a good clinical anti-cancer method which has high effectiveness and low toxicity.